Investor Event Attendance and Presentation

21 October 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Investor Event Attendance and Presentation

Open Orphan presents at The London Investor Show

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at The London Investor Show at Novotel London West, London, W6 8DR this Friday 25th October 2019.

Maurice Treacy, Open Orphan's Chief Commercial Officer, will be in attendance and will be presenting in Conference Room 1 from 11:50am - 12:20pm. Afterwards there will be an opportunity for existing and potential shareholders to discuss the Company's business plans moving forward.

The event will run from 09:30am - 5:00pm and all parties interested in attending can obtain a free ticket by using the promotional code OPENORPHAN19 when ordering a ticket from the following link: http://www.eventdata.co.uk/Forms/Form.aspx?FormRef=LISA9Visitor .

Enquiries:

Open Orphan Plc Tel: +353 (0)1 6440007Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.